Argus Upgrades Regeneron Pharma (REGN) to Buy, 'attractive entry point '
Tweet Send to a Friend
Argus analyst Jasper Hellweg upgraded Regeneron Pharma (NASDAQ: REGN) from Hold to Buy with a price target of $850.00.The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
